2016
DOI: 10.1016/j.bjid.2016.08.011
|View full text |Cite
|
Sign up to set email alerts
|

Aptamers as a promising approach for the control of parasitic diseases

Abstract: Aptamers are short single-stranded RNA or DNA oligonucleotides that are capable of binding various biological targets with high affinity and specificity. Their identification initially relies on a molecular process named SELEX (Systematic Evolution of Ligands by EXponential enrichment) that has been later modified in order to improve aptamer sensitivity, minimize duration and cost of the assay, as well as increase target types. Several biochemical modifications can help to enhance aptamer stability without aff… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
11
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
4
4

Relationship

1
7

Authors

Journals

citations
Cited by 21 publications
(12 citation statements)
references
References 70 publications
0
11
0
Order By: Relevance
“…NU172 has an IC 50 value of 5–10 μg/ml in plasma in an ecarin clotting time assay obtained by using thromboelastography (23). Currently, NU172 is the only thrombin binding aptamer evaluated in Phase II clinical trials (ClinicalTrials.gov identifier NCT00808964) for anticoagulation in heart disease treatments by ARCA Biopharma, Inc. (3,11,24,25). It induces a short-acting anticoagulation effect and is well tolerated without serious adverse responses (12).…”
Section: Introductionmentioning
confidence: 99%
“…NU172 has an IC 50 value of 5–10 μg/ml in plasma in an ecarin clotting time assay obtained by using thromboelastography (23). Currently, NU172 is the only thrombin binding aptamer evaluated in Phase II clinical trials (ClinicalTrials.gov identifier NCT00808964) for anticoagulation in heart disease treatments by ARCA Biopharma, Inc. (3,11,24,25). It induces a short-acting anticoagulation effect and is well tolerated without serious adverse responses (12).…”
Section: Introductionmentioning
confidence: 99%
“…A large body of biomedical research has shown that aptamers are better than other tools (e.g. antibodies) at detecting and inhibiting target molecules in diagnostics, therapeutics, and drug development 30 . In the present work, we used a systematic evolution of ligands by exponential enrichment (SELEX) protocol to identify RNA aptamers that target the EhCFIm25 protein.…”
Section: Introductionmentioning
confidence: 99%
“…Despite the fact that there has been a huge interest in aptamers and that countless scientific studies have been published on the topic, the full potential of aptamers in diagnostics and therapeutics have not yet come to fruition. The approval of Macugen ® (pegatnib sodium) an anti-vascular endothelial growth factor (VEGF) aptamer by the Food and Drug Administration in 2004 [15] for the treatment of age-related macular degeneration is a great milestone and demonstrates the potential of aptamers [14,37,53,128,129]. Since then, many more useful studies have been piloted in the search for solutions for the treatment of HIV, TB, ZIKA, Ebola, cancer, hepatitis and measles.…”
Section: Applications Of Aptamers For Viral Therapymentioning
confidence: 99%
“…Their specificity and affinity-binding properties make them important for use in different applications [11,12]. Although aptamers possess similar binding affinities for their targets as antibodies, varying between nanomolar and picomolar (expressed as dissociation constants, i.e., Kd) [13,14,15], antibodies are still not only immunogenic but is also associated with high production costs. On the other hand aptamers show great supremacy due to their lack of immunogenicity [10,16,17] and synthesis which is done chemically at lower costs, their small sizes makes them versatile and enables them to pass through blood-brain barriers which cannot be achieved with antibodies [18,19].…”
Section: Introductionmentioning
confidence: 99%